Posted by Michael Wonder on 13 Aug 2019
DNA data shared in ways patients may find surprising
12 August 2019 - Hospitals engaged in private deals with drugmakers don’t always disclose the ways the data will be used.
Deals between drug makers and hospital systems to mine the genetic profiles of hospital patients are triggering concerns over the control of valuable genetic data.
Drugmakers have been spending hundreds of millions of dollars for access to patient information because of the data’s potential to help unlock disease insights and discover new drugs. They are striking deals to sequence patients’ genetic code, including with hospital systems like Geisinger in Pennsylvania, Mount Sinai Health System in New York and Mayo Clinic in Minnesota.
